Pharmaceutical companies qualified to manufacture either active substances or medicines will now be able to produce cannabis-based medicines in France.
Manufacturing of clinical GMP batches of a new vaccine adjuvant, development of innovative cannabis-based medicines …
“Scaling up this kind of vaccine delivery system is a crucial step and requires a strong partner” says Dr. Didier Betbeder, CEO of Vaxinano.
Developing a French “patient to seed” ecosystem to improve the therapeutic benefit of medical Cannabis
“Simply replacing the imported products currently specified for the pilot program with French-produced equivalents would be a missed opportunity and a disservice to patients”
The complementary nature of their expertise and technologies will provide complete support for start-ups and SMEs from development through clinical trials.
Nanosizing drug particles brings key benefits for oral formulations of poorly soluble drugs such as Biopharmaceutics Classification System (BCS) Class II drugs.
SEPAREX, the gold standard in supercritical fluids, was founded in 1985 by Michel Perrut.
SEPAREX was also a pioneering business incubator, far ahead of its time, contributing to the birth of 8 companies.